SCNX Key Statistics, Chart & Performance
The current stock price of SCNX is 0.6326 USD. In the past month the price decreased by -15.28%. In the past year, price decreased by -91.6%.
SCNX Latest News, Press Relases and Analysis
SCNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 29.61 | 37.67B | ||
| DOCS | DOXIMITY INC-CLASS A | 27.46 | 8.48B | ||
| WAY | WAYSTAR HOLDING CORP | 22.69 | 5.82B | ||
| HTFL | HEARTFLOW INC | N/A | 2.39B | ||
| CERT | CERTARA INC | 18.56 | 1.48B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.36B | ||
| SDGR | SCHRODINGER INC | N/A | 1.32B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.09B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 634.75 | 1.08B | ||
| PHR | PHREESIA INC | N/A | 945.38M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 7.97 | 947.01M | ||
| HSTM | HEALTHSTREAM INC | 35.62 | 718.61M |
Related stock screener links
About SCNX
Company Profile
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Company Info
SCIENTURE HOLDINGS INC
20 Austin Blvd.
Commack NEW YORK US
Employees: 14
Phone: 18002610281
SCIENTURE HOLDINGS INC / SCNX FAQ
What does SCIENTURE HOLDINGS INC do?
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Can you provide the latest stock price for SCIENTURE HOLDINGS INC?
The current stock price of SCNX is 0.6326 USD. The price decreased by -2.9% in the last trading session.
Does SCIENTURE HOLDINGS INC pay dividends?
SCNX does not pay a dividend.
How is the ChartMill rating for SCIENTURE HOLDINGS INC?
SCNX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of SCNX stock?
SCIENTURE HOLDINGS INC (SCNX) operates in the Health Care sector and the Health Care Technology industry.
What is the Price/Earnings (PE) ratio of SCIENTURE HOLDINGS INC (SCNX)?
SCIENTURE HOLDINGS INC (SCNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
SCNX Technical Analysis
SCNX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SCNX. SCNX has a bad profitability rating. Also its financial health evaluation is rather negative.
SCNX Financial Highlights
Over the last trailing twelve months SCNX reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -283.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.61% | ||
| ROE | -24.86% | ||
| Debt/Equity | 0.01 |